Arvelle Therapeutics GmbH (aquired by Angelini Pharma)
Innovative treatments to patients suffering from cns disorders
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle received one of the largest initial financing commitments for a European-focused biopharmaceutical company.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
04.01.2021
Arvelle Therapeutics exits at a valuation of $960 million (startupticker.ch)
14.09.2020
Arvelles Präparat darf in Deutschland für Härtefälle verwendet werden (startupticker.ch)
20.08.2020
First patients to soon benefit from Arvelle Therapeutics’ therapy (startupticker.ch)
23.07.2020
Prizes from around the world (startupticker.ch)
03.04.2020
Arvelle Therapeutics’ antiepileptic drug is a step closer to market entry (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Arvelle Therapeutics GmbH (aquired by Angelini Pharma)
Innovative treatments to patients suffering from cns disorders
Website:
www.arvelletx.com/
Headquarter:
Basel
Foundation Date:
January 2019
Technology:
- Biotech
Sectors:
- Biotech